UK Court Sides With Genentech In Eye-Treatment Patent Suit

Law360, New York (February 22, 2013, 3:35 PM EST) -- The U.K. Court of Appeal ruled Thursday that a treatment for macular degeneration developed by Regeneron Pharmaceuticals Inc. and Bayer Pharma AG infringes a patent held by Genentech Inc. and that the patent is valid.

The court rejected Regeneron's claims that a trial judge had incorrectly construed the claims of Genentech's patent, which covers ways of treating eye diseases, and should have invalidated it as anticipated, obvious and overly broad.

The appeals court concluded that there were no errors in the judge's validity findings and that...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.